When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...

Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Sen. Bernie Sanders said he agrees with billionaire Elon Musk that Defense Department spending is too high with little accountability.

With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Since 2018, Ozempic's net price has fallen from $531 to $290, or 45%. Since 2020, Rybelsus' net price has dropped from $376 to $296, or 21%. In contrast, Wegovy's net price has increased 21% since ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...